Noncoding RNAs in Atrial Fibrillation: Current Status and Prospect

J Cardiovasc Pharmacol. 2020 Jan;75(1):10-17. doi: 10.1097/FJC.0000000000000762.

Abstract

Atrial fibrillation (AF) is an important cause of cardiovascular morbidity and mortality. Current therapies for AF are ineffective, mainly due to incomplete understanding of the pathogenesis of AF. Atrial remodeling contributes to the occurrence and progression of AF, but molecular mechanisms underlying AF remain unclear. Noncoding RNAs, including microRNAs, long noncoding RNAs and circular RNAs, are now considered to play an important role in the pathophysiology of AF. In this review, we summarize recent evidence supporting the role of noncoding RNAs in AF and highlight their diagnostic and prognostic applications as potential biomarkers and therapeutic strategies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Action Potentials
  • Animals
  • Atrial Fibrillation / genetics
  • Atrial Fibrillation / metabolism*
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / therapy
  • Atrial Remodeling
  • Gene Expression Regulation
  • Genetic Markers
  • Heart Atria / metabolism*
  • Heart Atria / physiopathology
  • Heart Rate
  • Humans
  • RNA, Untranslated / genetics
  • RNA, Untranslated / metabolism*
  • RNA, Untranslated / therapeutic use
  • Signal Transduction

Substances

  • Genetic Markers
  • RNA, Untranslated